Literature DB >> 19759594

Health economics: Life in the balance.

Daniel Cressey.   

Abstract

Mesh：

Year:  2009        PMID： 19759594     DOI： 10.1038/461336a

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  2 in total

Review 1.  Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.

Authors:  J Thompson Coon; M Hoyle; C Green; Z Liu; K Welch; T Moxham; K Stein
Journal:  Health Technol Assess       Date:  2010-01       Impact factor: 4.014

2.  Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.

Authors:  Bernard Escudier; Anna Pluzanska; Piotr Koralewski; Alain Ravaud; Sergio Bracarda; Cezary Szczylik; Christine Chevreau; Marek Filipek; Bohuslav Melichar; Emilio Bajetta; Vera Gorbunova; Jacques-Olivier Bay; Istvan Bodrogi; Agnieszka Jagiello-Gruszfeld; Nicola Moore
Journal:  Lancet       Date:  2007-12-22       Impact factor: 79.321
  2 in total
  5 in total

Review 1.  Using comparative effectiveness research to inform policy and practice in the UK HHS: past, present and future.

Authors:  Kalipso Chalkidou; Tom Walley
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

2.  Sample size and power for cost-effectiveness analysis (part 1).

Authors:  Henry A Glick
Journal:  Pharmacoeconomics       Date:  2011-03       Impact factor: 4.981

3.  Sample size and power for cost-effectiveness analysis (Part 2): the effect of maximum willingness to pay.

Authors:  Henry A Glick
Journal:  Pharmacoeconomics       Date:  2011-04       Impact factor: 4.981

4.  Adherence to national guidelines for initiation of antiretroviral regimens in HIV patients: a Danish nationwide study.

Authors:  Tonny S Petersen; Stig E Andersen; January Gerstoft; Kristina Thorsteinsson; Carsten S Larsen; Gitte Pedersen; Court Pedersen; Niels Obel
Journal:  Br J Clin Pharmacol       Date:  2011-07       Impact factor: 4.335

5.  Quantitative medical cost-effectiveness analysis of molecular-targeting cancer drugs in Japan.

Authors:  Takeshi Ebara; Tatsuya Ohno; Takashi Nakano
Journal:  Daru       Date:  2013-05-25       Impact factor: 3.117
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.